Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: Cumulative toxicity profile?

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 600-601

  Ayllon, J ^a   Launay Vacher, V ^b   Medioni, J ^a   Cros, C ^b   Spano, J P ^b   Oudard, Stephane ^a,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CLODRONIC ACID; SUNITINIB; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CASE REPORT; HUMAN; HYPERCALCEMIA; JAW DISEASE; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LETTER; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 61649123793     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn788     Document Type: Letter

References (6)

1. Woo SB, Hellstein JW, Kalmar JR. Narrative review: BPs and osteonecrosis of the jaws. Ann Intern Med 2006; 144(10): 753-761.
2. McArthur HL, Estilo C, Huryn J et al. Osteonecrosis of the jaw among intravenous bisphosphonate - and/or bevacizumab - treated patients at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 2008; 26: (Abstr 9588).
3. Estilo CL, Fornier M, Farooki A et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008; 26(24): 4037-4038.
4. Santini D, Schiavon G, Angeletti S et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angiogenesis: A new role for these drugs? Recent Patents Anticancer Drug Discov 2006; 1(3): 383-396.
5. Allegra A, Oteri G, Nastro E et al. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 2007; 25(4): 164-169.
6. Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007; 79(1): 69-71.